Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Can PET Imaging Facilitate Optimization of Cancer Therapies?

Author(s): Gabriela Kramer-Marek and Jacek Capala

Volume 18, Issue 18, 2012

Page: [2657 - 2669] Pages: 13

DOI: 10.2174/138161212800492813

Price: $65

Abstract

Positron emission tomography (PET) has become an indispensable tool in the study of cancer biology, as well as in the clinical management of patients with cancer. Quantitative measurements of tracer accumulation enable researchers to detect tumor changes much earlier than by conventional imaging modalities. 18F-FDG has been widely utilized for staging and restaging of cancer, evaluation of response to the treatment, and assessment of prognosis; however, recently target-specific PET tracers have raised even more attention. This overview discusses the current status of PET imaging in optimization of cancer therapies in preclinical and clinical studies.

Keywords: Molecular imaging, PET, 18F-FDG, cancer therapy, cancer biology, prognosis, metastasize, CNS response, radionuclide, cell proliferation

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy